These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36180072)

  • 1. OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases.
    Thiele M; Donnelly SC; Mitchell RA
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36180072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions.
    Thiele M; Kerschbaumer RJ; Tam FW; Völkel D; Douillard P; Schinagl A; Kühnel H; Smith J; McDaid JP; Bhangal G; Yu MC; Pusey CD; Cook HT; Kovarik J; Magelky E; Bhan A; Rieger M; Mudde GC; Ehrlich H; Jilma B; Tilg H; Moschen A; Terhorst C; Scheiflinger F
    J Immunol; 2015 Sep; 195(5):2343-52. PubMed ID: 26209628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer.
    Schinagl A; Thiele M; Douillard P; Völkel D; Kenner L; Kazemi Z; Freissmuth M; Scheiflinger F; Kerschbaumer RJ
    Oncotarget; 2016 Nov; 7(45):73486-73496. PubMed ID: 27636991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis.
    Ferhat M; Mangano K; Mirkina I; Mayer J; Rossmueller G; Schinagl A; Kerschbaumer R; Nicoletti F; Thiele M; Landlinger C
    Eur J Pharmacol; 2023 Oct; 956():175997. PubMed ID: 37579967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redox-dependent plasticity of oxMIF facilitates its interaction with CD74 and therapeutic antibodies.
    Sajko S; Skeens E; Schinagl A; Ferhat M; Mirkina I; Mayer J; Rossmueller G; Thiele M; Lisi GP
    Redox Biol; 2024 Sep; 75():103264. PubMed ID: 38972295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the Cysteine 81 Residue of Macrophage Migration Inhibitory Factor as a Molecular Redox Switch.
    Schinagl A; Kerschbaumer RJ; Sabarth N; Douillard P; Scholz P; Voelkel D; Hollerweger JC; Goettig P; Brandstetter H; Scheiflinger F; Thiele M
    Biochemistry; 2018 Mar; 57(9):1523-1532. PubMed ID: 29412660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritis.
    Höllriegl W; Bauer A; Baumgartner B; Dietrich B; Douillard P; Kerschbaumer RJ; Höbarth G; McKee JS; Schinagl A; Tam FWK; Thiele M; Weber A; Wolfsegger M; Turecek M; Muchitsch EM; Scheiflinger F; Glantschnig H
    Eur J Pharmacol; 2018 Feb; 820():206-216. PubMed ID: 29274331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic.
    Rossmueller G; Mirkina I; Maurer B; Hoeld V; Mayer J; Thiele M; Kerschbaumer RJ; Schinagl A
    Mol Cancer Ther; 2023 May; 22(5):555-569. PubMed ID: 37067909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of oxidized Macrophage Migration Inhibitory Factor (oxMIF) with antibody ON104 attenuates the severity of glomerulonephritis.
    Ferhat M; Mayer J; Costa LH; Prendecki M; Tarazona AAP; Schinagl A; Kerschbaumer RJ; Tam FWK; Landlinger C; Thiele M
    PLoS One; 2024; 19(10):e0311837. PubMed ID: 39374239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The functions and clinical studies of macrophage migration inhibitory factor].
    Zhao R; Yao WJ
    Sheng Li Ke Xue Jin Zhan; 2014 Apr; 45(2):93-9. PubMed ID: 25069302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases.
    Hoi AY; Iskander MN; Morand EF
    Inflamm Allergy Drug Targets; 2007 Sep; 6(3):183-90. PubMed ID: 17897055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current developments of macrophage migration inhibitory factor (MIF) inhibitors.
    Xu L; Li Y; Sun H; Zhen X; Qiao C; Tian S; Hou T
    Drug Discov Today; 2013 Jun; 18(11-12):592-600. PubMed ID: 23466524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroimmunomodulation by macrophage migration inhibitory factor (MIF).
    Bucala R
    Ann N Y Acad Sci; 1998 May; 840():74-82. PubMed ID: 9629239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIF in autoimmunity and novel therapeutic approaches.
    Stosic-Grujicic S; Stojanovic I; Nicoletti F
    Autoimmun Rev; 2009 Jan; 8(3):244-9. PubMed ID: 18721909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor.
    Morand EF
    Intern Med J; 2005 Jul; 35(7):419-26. PubMed ID: 15958113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo.
    Fingerle-Rowson G; Koch P; Bikoff R; Lin X; Metz CN; Dhabhar FS; Meinhardt A; Bucala R
    Am J Pathol; 2003 Jan; 162(1):47-56. PubMed ID: 12507889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock.
    Calandra T; Bucala R
    J Inflamm; 1995-1996; 47(1-2):39-51. PubMed ID: 8913928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Migration inhibitory factor enhances inflammation via CD74 in cartilage end plates with Modic type 1 changes on MRI.
    Xiong C; Huang B; Cun Y; Aghdasi BG; Zhou Y
    Clin Orthop Relat Res; 2014 Jun; 472(6):1943-54. PubMed ID: 24569872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.
    Bilsborrow JB; Doherty E; Tilstam PV; Bucala R
    Expert Opin Ther Targets; 2019 Sep; 23(9):733-744. PubMed ID: 31414920
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel anti-inflammatory activity of epoxyazadiradione against macrophage migration inhibitory factor: inhibition of tautomerase and proinflammatory activities of macrophage migration inhibitory factor.
    Alam A; Haldar S; Thulasiram HV; Kumar R; Goyal M; Iqbal MS; Pal C; Dey S; Bindu S; Sarkar S; Pal U; Maiti NC; Bandyopadhyay U
    J Biol Chem; 2012 Jul; 287(29):24844-61. PubMed ID: 22645149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.